The above data suggested that some clinical characteristics and features of peripheral blood immune cells were associated with the efficacy of EGFR-TKI resistant NSCLC patients receiving ICI plus chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.